Alumis (ALMS) EBITDA Margin (2025 - 2026)
Alumis (ALMS) posted quarterly EBITDA Margin of 4999.74% for Q4 2025, up 10.41% quarter-over-quarter from 5580.45% in Q3 2025.
Alumis (ALMS) EBITDA Margin (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported EBITDA Margin for 1 consecutive years, with 4999.74% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBITDA Margin changed N/A year-over-year to 4999.74%; the TTM figure through Dec 2025 stood at 1886.06% (changed N/A YoY), while the FY2025 annual figure was 1886.92%, changed N/A from the prior year.
- EBITDA Margin grew to 4999.74% in Q4 2025 per ALMS's latest filing, from 5580.45% in the prior quarter.
- Across five years, EBITDA Margin topped out at 583.49% in Q1 2025 and bottomed at 5580.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.32 Bn | 132.47 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.35 Bn | 58.16 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 63.15 Bn | 58.01 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.96 Bn | 36.86 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 17.93% |
| 7 | Royalty Pharma | 27.67 Bn | 26.83 Bn | - | 19.75% |
| 8 | BioNTech SE | 27.52 Bn | 9.13 Bn | 668.28 Mn | -35.57% |
| 9 | Insmed | 26.98 Bn | 25.82 Bn | 358.27 Mn | -0.36% |
| 10 | Alumis | 3.06 Bn | 2.56 Bn | - | -8,956.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,956.38% |
| Dec 31, 2025 | -4,999.74% |
| Sep 30, 2025 | -5,580.45% |
| Jun 30, 2025 | -5,271.53% |
| Mar 31, 2025 | -583.49% |